Cargando…

Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland

BACKGROUND: Mutations in BRCA1 and BRCA2 genes are well-established risk factors of breast and ovarian cancer. In our former study, we observed that approximately 6% of unselected ovarian cancer patients in the region of Podkarpacie (South-East Poland) carry BRCA1 causative founder variants, which i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jasiewicz, Andrzej, Rudnicka, Helena, Kluźniak, Wojciech, Gronwald, Wojciech, Kluz, Tomasz, Cybulski, Cezary, Jakubowska, Anna, Lubiński, Jan, Gronwald, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981954/ https://www.ncbi.nlm.nih.gov/pubmed/35382848 http://dx.doi.org/10.1186/s13053-022-00219-z

Ejemplares similares

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

Genetic predisposition to male breast cancer in Poland
por: Szwiec, Marek, et al.
Publicado: (2021)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone
por: Galor, Anna, et al.
Publicado: (2013)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

HOXB13 mutations and prostate cancer in Poland
por: Kluźniak, Wojciech, et al.
Publicado: (2012)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

The APOBEC3B c.783delG Truncating Mutation Is Not Associated with an Increased Risk of Breast Cancer in the Polish Population
por: Gliniewicz, Katarzyna, et al.
Publicado: (2023)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
por: Lener, Marcin R., et al.
Publicado: (2017)

Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism
por: Jakubowska, Anna, et al.
Publicado: (2008)

Population Screening of CHEK2 Mutations in Poland
por: Cybulski, Cezary, et al.
Publicado: (2006)

Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers
por: Marciniak, Wojciech, et al.
Publicado: (2021)

Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population
por: Rogoża-Janiszewska, Emilia, et al.
Publicado: (2020)

Selected aspects of genetic counselling for BRCA1 mutation carriers
por: Gronwald, Jacek
Publicado: (2007)

BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population
por: Dębniak, Tadeusz, et al.
Publicado: (2018)

Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland
por: Baszuk, Piotr, et al.
Publicado: (2021)

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
por: Byrski, Tomasz, et al.
Publicado: (2012)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
por: Lubiński, J, et al.
Publicado: (2012)

Inherited NBN Mutations and Prostate Cancer Risk and Survival
por: Rusak, Bogna, et al.
Publicado: (2019)

Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?
por: Stempa, Klaudia, et al.
Publicado: (2021)

Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland
por: Gronwald, Jacek, et al.
Publicado: (2006)

Blood arsenic levels and the risk of familial breast cancer in Poland
por: Marciniak, Wojciech, et al.
Publicado: (2019)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Large deletion causing von Hippel-Lindau disease and hereditary breast cancer syndrome
por: Krzystolik, Karol, et al.
Publicado: (2014)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Survival from breast cancer in women with a BRCA2 mutation by treatment
por: Evans, D. Gareth, et al.
Publicado: (2021)

BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation
por: Suszynska, Malwina, et al.
Publicado: (2019)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

NBS1 Mutation and prognosis of prostate cancer
por: Wokołorczyk, Dominika, et al.
Publicado: (2012)

Prostate cancer screening based on genotyping for high risk founder alleles
por: Cybulski, Cezary, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_betvq6lek883e2ok738e2l51fn